Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Askbio Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 5 distinct art units, so examiner assignment is broader than technical-unit distribution. CONNORS, ALEXANDRA F is the busiest examiner, with 1 pending action.
The counts indicate that some art units contain more than one of the pending matters, while each examiner appears only once in the profile. Counsel should coordinate claim language and disclosure positions across the shared technical units, while preserving separate response strategies for each examiner. The CONNORS matter is one individual assignment rather than an identified concentration of the docket.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
| KASHYAP, ESHA PRAKASH | 1 | 100.0% | +0.0% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 60d overdue |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 32d overdue |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | — |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | — |
| 18557475 | CANNULA ASSEMBLY | KASHYAP, ESHA PRAKASH | — |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 60d overdue |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 32d overdue |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 17d overdue |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | — |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | — |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1632 | 1 |
| 3783 | 1 |
| 1631 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | 1633 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | 1632 | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18557475 | CANNULA ASSEMBLY | KASHYAP, ESHA PRAKASH | 3783 | §102§103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§103§112 | Final Rejection | 32d overdue | Pending | Feb 02, 2023 |
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 1633 | §103§112 | Non-Final OA | 60d overdue | Pending | Aug 04, 2022 |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 1672 | §112Other | Non-Final OA | 17d overdue | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAskbio Inc. has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Alexandra F Connors has the most, with 1 of Askbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
